#mab technologies

[daniboy81ba]

Apoio ao meu amigo Adailton no serviço de cabeamento de rede estruturada #flem #ipac #museudeartedabahia #mab #PontosDiversos #NoêmiaRêgo #Trabalho #Diversidade #respeito #Aprendizado #estudante #ti #estacio #dio #Digitalinnovationone #udemy #tecnologiadainformação #RedesDeComputadores #ADS #technology #suporte #analista #analistadesistemas #dev #devlife #bolhadev #programação #informática (em Museu de Arte da Bahia) https://www.instagram.com/p/Ci6TCd7ruAV/?igshid=NGJjMDIxMWI=

[howhow326]

Bayonetta 3: Viola Rewrite

(Just me screaming into the void on how I would fix Viola)

Part 1: Viola, but better

Long, long ago, there was nothing. Then there was Omne. Out of nothingness, she crafted around her a universe of Light, and the shadow of Darkness surrounding that light. She created every plant, animal, and angel. Such a grand act of creation was taxing, which lead to her eternal slumber. Without her divine will, the highest angels grew prideful and chose to rebel against her will. This rebellion lead to the first Armageddon, forever separating the world of Light from the World of Darkness. From the fires of that battle also came the World of Chaos, ruled by a feeble imitation of Omne's divine will called Æsir. The angels stayed in the Light, the humans were severed from reality in the profound World of Chaos, and the demons fell to Darkness... but not all of them. Half of the fallen ones clung to the World of Chaos. It was in the gaps of Æsir's order that these Fairies created worlds Twilight for themselves. And so it was that the Universe was split between the Trinity of Realities: Paradiso (Light), Inferno (Darkness), Purgatorio (Twilight), and Chaos.

Within every reality of the World of Chaos exists a prophecy that the union of Light and Dark would bring calamity to the World... but this is only the incomplete version of the true prophecy: the union of Light, Dark, and Twilight would signal the beginning of the end for the whole of existence...

(TLDR: Bayonetta having kids with Luka condemned the entire multiverse to destruction)

Ok so, Singularity is now Cernunnos, the King of the Winter Fairies and all of the Homunculi are called Unseelie now because they are all fairies now. Cern really wanted to take over the World of Chaos but Æsir stopped him from doing that... then main universe Bayonetta killed Æsir.

Seeing his chance, Cern rallied his his Fairies to wipe out the human race and take over. During his take over, Cern realized he could exponentially increase his power by killing and absorbing Bayonetta (who is still the Arch Eve in every universe). He also killed a lot of Lukas (who is still the Arch Adam in every universe) but didn't absorb his power because there was literally no need to (Luka is weak lol).

Cern comes across Viola's universe where he A) kills Jeanne, B) kills Luka, and C) kills Bayonetta in front of Viola. Instead of simply being unable to catch her, Cern allows Viola to run away because he sees her as simple "junk data" (In this version, Cern is still technologically advanced while still being a magical fairy).

Viola runs into main universe Bayo, and the two of them along with Jeanne set out to stop the Winter King. Along the way, Viola meets with Fortitudio and forms a "pact" with him in order to stop Cern from destroying Paradiso and Chaos (Fortitudio just wants to manipulate Viola lol).

After that the stuff with Strider happens and this causes to transform into her fairy form, but this time her fairy form has a Angel Wing and a Demon Wing. After the fight, Viola realizes that there must be more to herself and she wants to figure out what that is.

Viola then fights Strider for the last time in France and she ends up in Avalon Forest (the domain of the Spring Fairies). In the forest, Viola meets... Queen Mab! Instead of that stupid "conversation" with Lukaon, Queen Mab reveals to Viola that she is not only the princess of Purgatorio, but also the "Arch Seth Origin": a being that signals the beginning of the end of all things. This conversation bumbs Viola out a bit, so Queen Mab gives Viola Mab Dachi (Viola's starting Weapon is Shuraba now because I said so) and she makes a pact with Viola so they can fight the Winter King togather and save the multiverse.

The final boss fight with Singularity is basically the same as before, but instead of "Dark Eve" Viola fights "Dark Cernunnos" which is literally the same as Singularity but with a dark filter.

At the end of the game, Viola becomes Violetta and not Bayonetta because that's not who she is :)

Game play changes

Weapons: Shuraba > Mab Dachi (After French Chapters). Bull's Kiss is replaced by Pistols (the same thing as the shoot buttons pistols)

Demons: Cheshire <> Fortitudio (After Chinese chapters) <> Queen Mab (After the French chapters)

*Dodge button now functions the same way as Rodin's shield, activates witch time.

Part 2: My version of Viola

This version is a Bayojeanne kid because F you

Forget literally all of that old lore because it's gone now, Fairies don't exist. Luka is not the reincarnation of a magic fairy prince and he's not Arch Adam Origin. Strider is not real, he can't hurt you. Also in this version Luka is the one that goes on spy missions to rescue Sigurd which kills him.

This version of Viola is more like a fusion of Jeanne and Bayonetta (but leaning on Jeanne's side) personalities and appearances. In her universe, the war against Singularity happened years earlier and claimed Jeanne's life when she was a little girl. The Bayonetta from that universe wanted to keep Viola as far away from the fighting as possible, but Viola went against her orders and made a pact with Alrune so she could become a Umbra Witch.

From that point onward, the plot is still really samey: Singularity kills Viola's mom, so Viola escapes to the main universe and goes on a quest with our Bayonetta. This time around, Jeanne is adventuring along with them.

Instead of the Strider boss fights, Viola spars with Jeanne to prove that she is ready to be an Umbra Witch.

At the end of the game, Singularity stabs Luka in the back. Then he stabs Jeanne in the back. Then Bayo beats him up like three times. Then at the last second Jeanne swoops down and Bayo, Jeanne, and Viola all team up together to take down Singularity and Singularity calls the three of them "Arch Maiden, Mother, and Crone Origin".

Bayo summons that one demon that keeps killing everyone and it kills Bayo. Jeanne willingly goes into Inferno along with Bayo while leaving Viola behind.

Viola then fights Dark Eve, and claims the name Bayonetta!

Game play changes

Weapon: Alruna (Viola can also use all weapons in the game)

Demon: Alrune (Chesire is written out. Viola can control Alrune)

*Viola activates witch time by dodging she can only dodge two times in a row.

*She also has beast within (Cheetah/Raven/no bat within equivalent)

[artstar1997]

Here’s my Valentines Day Specials for this Faebruary. I drew my favorite ships here. I love Broppy, especially Coossy (@jade-green-butterfly’s shipping), and Emi x Prince D (@groovinyeen’s ship).

Judging by their outfits, the seven troll tribes as fairy courts in my fantasy au have different patterns and aesthetics on their fashion. The fashion of the fairies, the elves, and the rest of the fae kingdom is inspired by the renaissance, and the 14th and the 15th century high medieval fashion with different designs and patterns used on their outfits.

The Platinum Court are the top wealthiest fairy court and they are the dominant court (their past rulers, Finvarra, Oona, Oberon, Titania and Mab are the members of the court) of the fairy kingdom so their outfit has shimmering patterns of constellations, stars, suns, and moons, which show their mastery in light magic.

The Funk Court are the second wealthiest because they are technologically advanced and they benefit from the Platinum Court due to their trades with the elves and other species. The patterns of their outfits are more psychedelic themed and retro themed because they master mind magic.

The Classical Court are the third wealthiest and they display their affinity for air magic by wearing outfits with feather, clouds and weather prints.

The Pop Court are obviously into energy magic so they wear clothes with bright, loud colors, but they prefer flower prints and woodland patterns because their kingdom is located deep in the forest. Poppy wears a cone-like hat called a hennin, which she still wears even when she becomes queen. As for Jussy, she wears an escoffion.

The Techno Court have a strong affinity with the sea and the element of water so their outfits have a pirate-like mix and they show it off with aquatic inspired details and fish scale prints.

The Hard Rock Court prefer to show their pride in their warrior culture by incorporating armor into their fashion, just like Emi’s customized funk outfit. They show off their warlike strength and their affinity for fire magic by adding dragon wings, horns, armor, and spikes with their clothes in black, gray, red and in muddy shades of different colors, usually blue, purple, indigo and many more. The prints they use are usually dragon scales, flames, and lava prints.

The Country Court are the most humble of the fairy courts because they were primarily farmers and they look nice but don’t let it fool you, they are also formidable warriors and they are known for their hunting and riding skills. Their fashion also reflect their agricultural way of life through beige tone colors, flower, leaf and plant prints and patterns.

Jussy belongs to @jade-green-butterfly Emi belongs to @groovinyeen Trolls belong to Dreamworks

[ahiddenpath]

Life Update

Just checking in.

It's been going... mixed, lately? Nothing terrible, but I have a lot on my mind. I feel in flux, like I'm at an indiscernible turning point and need to make a huge decision.

Work and Life Choices

My work stress levels are on the high end, recently. I'm bringing a new assay to the company, and that's been difficult because... I can't ask anyone for help. No one has the knowledge, lol! My first trial run was a huge success, and I'm a bit blown away. Basically, work keeps asking me to do novel stuff with little support, and I just... Keep?? Delivering???? And I realize this sounds braggy, but like- No one is more surprised than I am, believe me.

Meanwhile, I was asked to help with selecting a lead candidate for a project, which is totally new to me and was always the responsibility of folks one, two, or more "steps" above me in the company hierarchy. I've never been given this opportunity, but also... The only reason I made headway is because a senior colleague kindly helped me. HOWEVER, my manager asked me to meet with him before showing my plan to the project co-lead, since I'm new to this. AND THEN HE PEACED OUT TO A CONFERENCE FOR A WEEK AND LEFT TWO DAYS EARLIER THAN EXPECTED. So. That really stressed me out! I still don't really know how to handle it, but you can only maintain that level of stress for so long. You eventually enter the universe of, "I cannot be fucked. I am unfuckable."

Although as an asexual bean lol-

The good news is that it really benefits me to gain this knowledge- it's within my wheelhouse, but it's always been considered above my pay grade until now. Contrast this with bringing new technologies to the company and working with new formats. Folks keep asking me how to use the machine that can purify mAbs (basically the most... simple/common antibody format used in biotech), and I keep telling them... I've never been assigned mAb work, so I have no idea. I'm over here working with VHH and IgA and weird multispecifics exclusively.

I got another email on Friday where my boss assigned me more novel stuff I've never done. I can't exactly argue when he's in a conference, but... I am... Unsure... How I can get all of this done, lmao???

On the other hand, I dove into my work benefits to figure something out, and I realized that... Um, my total compensation package is... Well, it's a lot better than anything I've had before, in terms of money. It's... Uh, it's a mixed feeling. Obviously, it's great to be paid better than I ever have been. But it also makes me feel more locked into this career and this place, because... It's finally "paying off." My husband and I have been talking about starting a family, but I told him that I don't see myself having children in a household with two working parents and no support.

This is deeply personal, and obviously income plays a role, too. Many American families cannot afford two working parents, because daycare costs more than one or both parents' salaries. In our case, I make less than my husband, but after taxes and contributing to retirement, daycare would cost about 45% of my remaining take home.

However.

On Friday, I asked a colleague who I just met how she was doing. She had dark bags under her eyes- the kind of thing written about in novels, but rarely seen in real life. And she replied, "Well, I haven't been able to stop working long enough to eat for a few days. I came home and my children were needy and we have a new puppy who was wrecking things and I just went in my room and shut the door and sobbed."

That was a bit intense for a first ever "how are you," but regardless... This is so many women I know, including my mother. I absolutely have seen involved and loving husbands/fathers, but I've seen more who work and then vanish into the mancave the rest of the time. I have a teammate who purposefully works from 1-7 PM to avoid his kids and inlaws, leaving childcare, food, and housework to his wife (and frankly, he made me do his work for half a year until I cracked and told my boss to remove me from working closely with him). My husband is a gem who frankly takes care of me more than I take care of him, so I don't have to fear this, but...

Well, we don't have support. It would be us vs the world with a baby, and my country offers nothing to help families out. And, as we all know, the costs needed to live (housing, healthcare, education, food) are drastically rising.

I really do not know what the next steps in my life are, and I'm already at the point of "geriatric" pregnancy (mid thirties). Do I keep up with this challenging, interesting career that pays well, but is incredibly stressful? Do I have a child and give up the career? Do I try to do it all (two parents who work full time and a kid)? Will I end up like my colleague if I do that? Will giving up my job make me feel unfulfilled? Will the loss of income wreck me someday?

Stress, Creating, Self Care

So, like... I've been stressed, as you might notice. My ear started ringing, with varying intensity and pitch, so I couldn't sleep on Thursday night. Thankfully, it stopped after about 24-32 hours, because I was losing my mind! The internet listed stress as a cause, and... Yeah, I'm thinking it's that.

On top of this, my husband was away for work from Wednesday to Saturday, so I ran the house by myself and was on my own. I was slammed last week and did not have any mental juice to spare.

I haven't done much creatively in February. I can't get my brain to do it, but I'm also not really trying? Usually, when I'm not creating, Bad Things are happening. I'm not sure if I'm there or not, or if I just have other things going on right now? I am getting the sense that I need to do more for myself. I'm not... Sure... What that is, though.

I'm thinking exercise. I gained weight over the pandemic, and lately I feel physically and mentally lethargic. So... Eating better and exercise are probably what I should focus on right now?

I can never seem to keep the mental health, physical health, work, relationships, and chore balls in the air. I tend to drop the physical health ball most readily, which goes about as well as you'd imagine.

I'm hoping to figure out what fun stuff my husband and I might do this year. I need something to look forward to, because it's been so easy (tempting, even?) to feel overwhelmed by all the scary and uncertain things.

I have not been creating, and I have not been online much. Apologies for that. It's one of those "my cup is empty" periods, but I'm not in trouble. I'm just sort of... Looking at the empty cup and going, "Hmm. I should fill this, but, uh... How?" And also, "What kind of cup do I want in the future?"

I truly hope you're all taking care and holding on and finding ways to flourish. It's hard, man. I'm wishing you wellness, kindness, love, growth, support, and well-being. Thanks for caring about me <3

Love,

Hidden

[presidentstalkeyes]

@gf10yearslaterzine

Bit late to the punch, so I've got three to get through:

1: Now this is a toughie, I could make an argument for almost any character. I could say Mabel, for her idealism and ability to be sincere about literally everything; I could also say Wendy for just being the coolest, so cool that just by being around her you become more confident (and I might be biased because I cosplayed as her once :V).

But after thinking about it, I'm gonna have to say... Pacifica.

Why? Odd choice, yes. I'm probably the only one who picked her. Admittedly I'm heavily influenced by the fandom interpretation of her character as well. I guess I just really appreciate how the show gave her some actual depth when it totally didn't have to, and honestly I can weirdly relate a lot to an awkward privileged girl who's constantly checking her behaviour, worried about slipping back into old habits and wondering if anyone else notices or even cares. She also makes a good foil for Gideon, and perfectly demonstrates how it's nurture, not nature, that defines a person. ...Okay, and I might just gravitate towards the Alpha B*tch characters. :V

2: This one's a toss-up between the page where Dip & Mab trick Soos into thinking they're from the future (and literally the day before they run into Blendin, to boot) and COMPY THE COMPSOGNATHUS. Stan had a good pet that understood him! The entire run-up to Ford's portal test was also pretty creepy and helped paint his whole character as a glory hound, very different from how he was in the show.

3: Another odd choice, buuuut... Rumble McSkirmish and GifFany. Possibly because I'm more into sci-fi than fantasy, and so their technological origins speak to me, but also because of that, they imply a lot about Gravity Falls' weirdness, how it can even affect modern technology rather than going with the 'magic and technology don't mix' cop-out. GifFany's also pretty terrifying on a conceptual level. I mean, most creepy-ass stalkers can't approach you literally anywhere where there's a screen or turn your home appliances against you.

It helps that their respective episodes are some of my favourites, Fight Fighters because I'm fighting game trash and so were the writers given how many references they stuffed in there, and Soos and the Real Girl because Soos wasn't treated as a comical butt-monkey and actually found someone who genuinely likes him. But I'm getting ahead of myself.

[articleeee]

Continuous Bioprocessing Market is projected to reach $1.32 billion by 2031

Meticulous Research®– a leading global market research company published a research report titled “Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2028”. 

Download free Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5079?utm_source=article&utm_medium=social+&utm_campaign=product&utm_content=15-05-2024

According to this latest publication from Meticulous Research®, the continuous bioprocessing market is expected to grow at a CAGR of 23.0% from $100.75 million in 2021 to $429.12 million by 2028. The growth in the overall continuous bioprocessing market is mainly attributed to the growing demand for biopharmaceuticals, growing development of new technologies and products related to continuous bioprocessing, and rising government support for biopharmaceutical manufacturing. In addition, significant opportunities from emerging Asia-Pacific and Latin American regions and growing approval for personalized medicines further support this market's growth. However, factors such as the high risk of contamination with continuous bioprocessing, the complex and technically unfeasible nature of continuous bioprocessing in downstream processes, and shortage of bioprocessing professionals are expected to hinder the adoption of continuous bioprocessing.

Continuous Bioprocessing Market:  Future Outlook

The global continuous bioprocessing market study presents historical market data in terms of values (2019 and 2020), estimated current data (2021), and forecasts it for 2028– Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels.       

Browse in depth: https://www.meticulousresearch.com/product/continuous-bioprocessing-market-5079?utm_source=article&utm_medium=social+&utm_campaign=product&utm_content=15-05-2024

Based on product, the filtration systems and consumables segment accounted for the largest share of the market in 2020. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.

Based on application, the research and development segment is expected to grow at the highest CAGR during the forecast period. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.

Download request sample report here; https://www.meticulousresearch.com/request-sample-report/cp_id=5079?utm_source=article&utm_medium=social+&utm_campaign=product&utm_content=15-05-2024

Based on end user, the CDMOs and CROs segment is expected to grow at the highest CAGR during the forecast period. Rising investments in CDMOs and CROs and the gradual shifting of CDMOs from batch to continuous manufacturing are driving the market growth.

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of the global continuous bioprocessing market, followed by Europe and Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.

The key players operating in the continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).

Quick Buy: https://www.meticulousresearch.com/Checkout/13717155?utm_source=article&utm_medium=social+&utm_campaign=product&utm_content=15-05-2024

Contact Us:

Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[bhushans]

The Rise of Tech-Driven Therapies: Reshaping the Global HER2 Positive Gastric Cancer Market

The global HER2-positive gastric cancer treatments market is expected to grow at a compound annual growth rate (CAGR) of 3.5%, with a current valuation of US$ 1261.8 million by 2023. Healthcare technology advancements are expected to drive the market to US$1779.8 million by 2033.

The market for gastric cancer that is HER2-positive will likely experience rapid expansion as more people become aware of the symptoms and causes of the illness.The market is expected to develop due to an increase in product releases and approvals, as well as increased business activity in conducting clinical trials to find effective treatments for patients with stomach cancer that is HER2 positive.

For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product, to treat HER-2 positive stomach cancers that have spread. Additionally, it is projected that the market’s growth would be aided by the increasing number of drugs in the pipeline that are gaining special designations.

Reveal Patterns With Your Sample Report Preview: https://www.futuremarketinsights.com/reports/sample/rep-gb-16232

North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million

From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR

By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million

Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.

China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033

“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.

Competitive Landscape

AstraZeneca

Bayer

Bristol-Myers Squibb

Ono Pharmaceutical Co. Ltd

Hutchison Medipharma

LintonPharm

Shanghai Henlius Biotech

Sanofi

Pfizer

Novartis AG

Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.

In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.

In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

Chemotherapy

Immunotherapy

Radiation Therapy

Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

Stage I

Stage II

Stage III

Stage IV

HER2 Positive Gastric Cancer Market by End-User:

Ambulatory surgery centres,

Hospitals and Specialty clinics

Others

[tritonmarketresearchamey]

Bioengineered Protein Drugs Market: Trends Fuel Advanced Remedies

As per IDF Diabetes Atlas 10th edition, around 537 million adults are diagnosed with diabetes globally; this number is anticipated to surge to 643 million by 2030. Type 1 diabetes is among the most common autoimmune diseases, followed by lupus, rheumatoid arthritis, and psoriasis. According to the National Stem Cell Foundation, nearly 4% of the world’s population is distressed by at least 1 out of 80+ diseases. Such high prevalence has increased the adoption of bioengineered protein medications due to high affinity and low toxicity. Based on our estimates, the global bioengineered protein drugs market is predicted to witness progress with a CAGR of 7.7% during the forecast period 2023-2030.

The burden of diseases due to the rising aging population has elevated the demand for advanced medications. As per the World Population Prospects 2019, 1 in 6 people will be over 65 globally by 2050. This has prompted advancements in biotechnology and protein engineering, resulting in the availability of various drugs, including monoclonal antibodies, peptide hormones, vaccines, and fusion proteins.

Let’s look deeper into the key trends prompting developments in drug delivery systems, leading to the bioengineered protein drugs market’s expansion.

·         Rising Chronic Cases Amplifies Recombinant Proteins’ Application

Over the past decade, the incidence rate of chronic diseases has soared due to unhealthy lifestyles. According to WHO, more than 15 million people between 30-69 years decease from chronic conditions annually. Cardiovascular disease accounts for most non-communicable disease mortality, followed by cancers, diabetes, etc. This has led to a significant shift in the pharmaceutical industry from chemical drugs to protein drug development. For instance, between 2021 and 2022, the US FDA approved 19 mAbs, 6 peptide hormones, 1 fusion protein, 4 therapeutic enzymes, etc.

Protein drugs using recombinant DNA technology have gained significant traction recently, leading to various launches. For instance, in February 2023, Researchers at the Indian Institute of Technology (IIT) Guwahati developed a ‘Recombinant Protein Toolbox’ consisting of six proteins that convert skin cells into heart cells, especially cardiomyocytes. This toolbox regenerates damaged heart tissues using DNA technology.

·         Manufacturing Advancements Widen Drug Scope

Earlier, protein drugs were obtained from humans or other resources. For example, vaccines were formulated using egg cultures. However, recombinant DNA technology has enabled manufacturers to produce bioengineered protein drugs like vaccines, monoclonal antibodies, and blood factors using genetically modified organisms. To elucidate, blood products can be manufactured using DNA technology in bacterial expression or mammalian cell culture systems. The prominence of protein engineering platform technologies is mainly owing to their ability to enhance medications’ functionality, purity, and circulating half-life. Protein conjugation and derivatization are among the major approaches that elevate circulating half-life.

Advancements in protein engineering have led to further R&D investments in protein-based drug manufacturing. For instance, in March 2023, Eli Lilly and Company invested $1.5 billion to expand its manufacturing footprint with new facilities in North Carolina, Indiana, and Ireland. Its facility in Ireland is set to be the most technically advanced manufacturing site for existing monoclonal antibodies, producing existing and pipeline clinical products by 2026. Hence, drug manufacturing and delivery advancements create opportunities for the bioengineered protein drugs market.

Growth Projections: R&D Expands Treatment Possibilities

Considering the rising demand for effective therapies and high unmet needs, healthcare companies are surpassing research boundaries to improve treatments. This has led the pharmaceutical industry to move towards novel molecular formats to deliver breakthrough therapies. Moreover, rare diseases with few or no treatment drugs have influenced players to expand research capabilities and launch new drugs. Since numerous factors drive many complex conditions, constraining one target may not prosper in achieving efficiency. In such a scenario, developing multi-specific antibody formats treats multi-layered diseases by engaging two or more targets with one molecule. Therefore, rising research and development activities are expected to boost the bioengineered protein drugs market.

 

FAQs:

Q1) Which region holds the highest share in the bioengineered protein drugs market?

North America holds the highest share of the global market.

Q2) Which are the major bioengineered protein drug types?

Monoclonal antibodies, peptide hormones, vaccines, blood factors & peptide antibiotics, fusion proteins, cytokines, and therapeutic enzymes are major drug types.

[kirnakumar155]

MAB Ariba

MAB Ariba: Streamlining Procurement for Efficiency and Savings

In today’s fast-paced business landscape, optimizing procurement processes is essential for maximizing resources and maintaining a competitive edge. MAB Ariba, an integration between Malaysia Airlines Berhad (MAB) and the SAP Ariba platform, offers a powerful solution to streamline procurement, driving efficiency and cost reduction.

What is MAB Ariba?

MAB Ariba is a cloud-based procurement platform tailored explicitly to Malaysia Airlines Berhad’s needs. It leverages the power of SAP Ariba, a global leader in spend management solutions. This platform allows MAB greater control and visibility over its procurement and sourcing functions.

Key Features of MAB Ariba

MAB Ariba offers a wide range of features designed to transform procurement operations:

Supplier Management: Simplifies the process of finding, onboarding, and managing suppliers. MAB can easily track supplier performance, ensure compliance, and build stronger business relationships.

Spend Analysis: Provides in-depth insights into MAB’s spending patterns, identifying areas for cost savings and potential process improvements.

E-Sourcing: Enables MAB to run competitive bidding events (RFXs, RFPs, and auctions) efficiently and digitally, ensuring they get the best value for their money.

Contract Management: Streamlines the creation, negotiation, and storage of contracts, reducing risks and ensuring all parties are on the same page.

Catalog Management: Maintains a centralized repository of approved products and services, making it easier for internal teams to find what they need.

Benefits of using MAB Ariba

Adopting MAB Ariba delivers numerous advantages for Malaysia Airlines Berhad:

Cost Savings: MAB can identify opportunities to reduce spending, negotiate better deals with suppliers, and improve overall procurement efficiency.

Enhanced Visibility: MAB gains real-time insights into their spending, facilitating better decision-making and control over the budget.

Process Automation: The platform automates tedious and time-consuming procurement tasks, freeing employees to focus on more strategic initiatives.

Improved Compliance: MAB can ensure adherence to internal policies and external regulations, mitigating risks and avoiding costly penalties.

Collaboration and Communication: MAB Ariba fosters better collaboration between internal stakeholders and suppliers, streamlining communication and reducing delays.

Getting Started with MAB Ariba

If you are a supplier interested in working with Malaysia Airlines Berhad, you’ll likely need to interact with the MAB Ariba system. It’s helpful to familiarize yourself with SAP Ariba and its standard features:

Supplier Training and Support: Use the resources offered by SAP Ariba to understand their platform and processes.

The Future of Procurement

MAB Ariba represents a significant step forward for Malaysia Airlines Berhad, which is embracing the power of technology to optimize its procurement strategy. As cloud-based procurement solutions continue to evolve, businesses of all sizes can expect even greater efficiency, transparency, and cost reduction in the years to come.

You can find more information about  SAP ARIBA in this  SAP ARIBA Link

 

Conclusion:

Unogeeks is the No.1 IT Training Institute for SAP  Training. Anyone Disagree? Please drop in a comment

You can check out our other latest blogs on  SAP ARIBA here – SAP  ARIBA Blogs

You can check out our Best In Class SAP ARIBA Details here – SAP ARIBA Training

Follow & Connect with us:

———————————-

For Training inquiries:

Call/Whatsapp: +91 73960 33555

Mail us at: info@unogeeks.com

Our Website ➜ https://unogeeks.com

Follow us:

Instagram: https://www.instagram.com/unogeeks

Facebook: https://www.facebook.com/UnogeeksSoftwareTrainingInstitute

Twitter: https://twitter.com/unogeek

[daniboy81ba]

Na semana do estudante, eu volto a sala de aula, dando início a mais uma jornada para buscar mais conhecimentos sobre a tecnologia da informação e suas variáveis🧑‍💻 #gorvernodabahia #educacao #govba #secultba #ipac #flem #museudeartedabahia #mab #botefenaesperança #cultura #culturaquemovimenta #tecnologiadainformação #ADS #technology #suporte #analista #analistadesistemas #dev devlife #programação #informática #dev #devlife #bolhadev (em Ceep Isaías Alves) https://www.instagram.com/p/ChJR4iAMdfj/?igshid=NGJjMDIxMWI=

[cbrnergeticsltd-blog]

We are an industry leading biological detection equipment supplier.  We are the UK partner for all Proengin CBRN detection equipment that uses flame photometry technology.  MAB is used worldwide as a biological alarm monitoring system.  AP4C-VB and AP4C-FB provide the ideal solution for vehicle, infrastructure, and naval biological detection and monitoring requirements.

[ottawageneralcontractors1]

Transform Your Garage: Unique Customization Ideas for Your Home

Elevate your home with innovative garage addition ideas. From smart home integrations and multifunctional workspaces to artistic wall murals and vertical gardens, this guide offers a range of creative solutions for customizing your garage space. Perfect for homeowners seeking to blend functionality with personal style

[ama2024]

https://www.advancemarketanalytics.com/reports/34091-global-styrenic-polymers-market

Styrenic Polymers Market: Study Navigating the Future Growth Outlook

Advance Market Analytics released a new market study on Global Styrenic Polymers Market Research report which presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for Global Styrenic Polymers Forecast till 2029*.

Styrenic polymer is formed by polymerization of styrene in the presence of vinyl group results. The styrene based resins are widely applicable in manufacturing wide variety of everyday goods, kitchen appliances, hospitals and school supplies. The styrenic polymers offer several facilities such are flexibility of materials and design in the field of medical industries. There has been significant rise in number of polymer production capacity with figure stood up to USD 10.8 million ton in global in 2016, the future for styrenic polymers looks promising. The major companies are introducing latest technology based styrenic polymers in Asia-Pacific and Middle East region as its demand is observed in electrical and electronics industries that consume a majority of styrenic polymers.

Key Players included in the Research Coverage of Styrenic Polymers Market are:

Bayer Material Science (Germany), Lanxess Ag (Germany), Saudi Basic Industries Corporation (Saudi Arabia),  Nova Chemicals Corporation (Canada), ENI S.P.A, LG Chem Ltd. (South Korea), Ashland (United States), Styrolution Group GmbH (Germany), Ineos Group Ag (Switzerland), Asahi Kasei Corporation (Japan), Alpek Sab De Cv (Mexico), BASF(Germany),

What's Trending in Market: Rising Demand of styrenic polymers due to urbanization and industrialization. increasing demand of styrenic polymers in automobile industry at South America region.

Challenges: Adverse Impact Due to Economic Uncertainties in Styrenic Polymers.

Opportunities: Introduction Of New Models and Technology Advancements Expected to Boost the Business Jet Market. Rapid Technological Innovation Leads to Propel the Market.

Market Growth Drivers: Increase In Demand of Lightweight Materials in Consumer Goods Industries. Rise In Demand Of Styrenic Polymers in Asia-Pacific Regions Fuelled Up The Market.

The Global Styrenic Polymers Market segments and Market Data Break Down by Type (Polystyrene (PS), Acrylonitrile Butadiene Styrene (ABS), Styrene Acrylonitrile (SAN), Methacrylate Butadiene Styrene (MBS), Methacrylate Acrylonitrile Butadiene Styrene (MABS), Styrene Methyl-Methacrylate (SMMA), Styrene Butadiene Styrene (SBS), Styrene Ethylene Butylene Styrene (SEBS), Others), Application (Medical, Building and Construction, Electrical and Electronics, Automotive Industry, Consumer Goods, Other), Process (Geometric, Fluid-Dynamic, Thermodynamic)

Get inside Scoop of the report, request for free sample @: https://www.advancemarketanalytics.com/sample-report/34091-global-styrenic-polymers-market

To comprehend Global Styrenic Polymers market dynamics in the world mainly, the worldwide Styrenic Polymers market is analyzed across major global regions. AMA also provides customized specific regional and country-level reports for the following areas.

• North America: United States, Canada, and Mexico.

• South & Central America: Argentina, Chile, Colombia and Brazil.

• Middle East & Africa: Saudi Arabia, United Arab Emirates, Israel, Turkey, Egypt and South Africa.

• Europe: United Kingdom, France, Italy, Germany, Spain, Belgium, Netherlands and Russia.

• Asia-Pacific: India, China, Japan, South Korea, Indonesia, Malaysia, Singapore, and Australia.

[jcmarchi]

Manipulating Polyamines to Enhance Antibody Efficacy: A Novel Approach in Biotechnology - Technology Org

New Post has been published on https://thedigitalinsider.com/manipulating-polyamines-to-enhance-antibody-efficacy-a-novel-approach-in-biotechnology-technology-org/

Manipulating Polyamines to Enhance Antibody Efficacy: A Novel Approach in Biotechnology - Technology Org

Monoclonal antibodies (mAbs) are laboratory-designed proteins that mimic the immune system’s antibodies. To date, many therapeutic mAbs belonging to the immunoglobulin G (IgG) class of antibodies have been approved for treating cancer and autoimmune diseases. Cell lines such as the Chinese hamster ovary (CHO) cells are generally used to produce mAbs. Notably, the production and manufacture of mAbs are regulated by critical quality attributes (CQAs) to ensure their safety and efficacy in treatment.

An important CQA for mAbs is the N-linked glycosylation present at a specific position (Asn297). N-linked glycans consist of N-acetylglucosamine (GlcNAc), mannose (Man), fucose (Fuc), galactose (Gal), and sialic acid. The heterogeneity of the N-linked glycan profiles of mAbs can be attributed to the different numbers and linkages of additional saccharides. The composition of N-linked glycans affects the overall therapeutic efficacy, targeting ability, and immune-specificity of these antibodies. For example, antibody-dependent cellular cytotoxicity (ADCC) is influenced by the fucosylation and galactosylation of N-linked glycans. Complement-dependent cytotoxicity (CDC) is also affected by the galactosylation and sialylation of N-linked glycans. Hence, it’s crucial to meticulously regulate N-linked glycan profiles throughout the manufacturing process because the heterogeneity of the N-linked glycan profile of mAbs depends on the cell culture duration and changes in nucleotide sugars and glycosylation enzyme levels.

Recently, Dr. Kyohei Higashi, Associate Professor at Tokyo University of Science (TUS) in Japan, along with a team of researchers including Dr. Rin Miyajima and Dr. Masahiro Komeno, conducted a study to explore the effects of polyamines on N-linked glycan profiles of mAbs in CHO DP-12 cells. Their work was made available online on November 3, 2023 in the Journal of Biotechnology.

“Because the carbohydrate structure of mAbs changes depending on the state of the cells, we were interested in investigating the relationship between intracellular polyamines and the carbohydrate structure of mAbs from CHO cells.” explained Dr. Higashi, when asked about the motivation behind the research.

Polyamines (putrescine, PUT; spermidine, SPD; and spermine, SPM) are present in millimolar concentrations in all living organisms and play essential roles in normal cell growth and differentiation. PUT, SPD, and SPM contained two, three, and four amino groups, respectively. PUT is synthesized from ornithine (ORN) by ornithine decarboxylase (ODC), a rate-limiting enzyme in the polyamine biosynthesis pathway. SPD is synthesized from putrescine by spermidine synthase, and spermine is synthesized from spermidine by spermine synthase. Intracellular polyamine levels are regulated at various steps, including synthesis, degradation, and transport, and are affected by external stimuli, aging, and diseases. Because CHO cells lack arginase activity to produce ORN from arginine, they cannot produce polyamines in serum-free media, resulting in a decrease in intracellular polyamine levels, which causes a low growth rate and cell viability during long-term cultivation.

Intracellular polyamine levels can also be decreased by treatment with α-difluoromethylornithine (DFMO), an inhibitor of ODC. The depletion of intracellular polyamines by DFMO can be reversed by the addition of SPD to the growth media of CHO cells.

Upon introducing DFMO to the CHO cells, the team observed that IgG antibody galactosylation surged, along with an increase in the levels of β1,4-galactosyl transferase 1 (B4GALT1) mRNA. This mRNA is pivotal in governing the IgG galactosylation mechanism within CHO cells. What’s more, IgG production decreased by approximately 30% in DFMO-treated cells.

Dr. Higashi hypothesized that the decrease in IgG production was a result of endoplasmic stress (ER) stress response caused by polyamine depletion. During ER stress response, protein folding ceases, resulting in the arrest of the normal function of cells. Chaperone proteins assist in the correct folding of other protein classes and play a crucial role under both normal and stress conditions. The results of the ER stress response study confirmed the increased expression levels of chaperones for glycoprotein folding, in polyamine-depleted cells.

The team further observed that upon using tunicamycin, an ER stress inducer inhibiting N-glycosylation, ER stress from polyamine depletion triggered B4GALT1 mRNA expression, increasing IgG galactosylation in CHO cells.

Image title: Effect of polyamines on the N-glycan structures of antibodies Image caption: Japanese researchers investigated how polyamines affect the functional profile of monoclonal antibodies and their production from CHO cells, and found that spermidine supplementation contributes to the maintenance of IgG production and N-galactosylation. Image credit: Kyohei Higashi from Tokyo University of Science

The ability to maintain antibody glycosylation profiles via polyamine modulation has numerous implications. Controlled glycosylation is crucial for optimizing therapeutic proteins, such as antibodies, ensuring the stable production of antibodies in a uniform manner of biological activities, and potentially decreasing the manufacturing cost. Supplementation of polyamine could be accomplished by the addition only of SPD to serum-free medium, offer an easy and costless method to maintain the glycan structure of mAbs produced by CHO cells cultured in the serum-free medium. This insight might influence cell line development and bioproduction, facilitating the creation of biosimilars.

“Introducing polyamines, particularly SPD, to serum-free culture medium for CHO cells may contribute to consistent manufacturing and quality control of antibody production. We hope that this research will contribute to the stable production of antibody drugs and lead to lower drug prices” concludes Dr. Higashi.

Source: Tokyo University of Science

You can offer your link to a page which is relevant to the topic of this post.

[deshpandeisha]

The Revenue : Mapping Monoclonal Antibodies Market Trends

The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast period. Rising adoption in personalized medicine and precision therapies, expanding regulatory approvals of monoclonal antibodies by regulatory agencies across the globe, and increasing technological advancements in biotechnology and immunology are some of the factors expected to drive market revenue growth.

The report also discusses in detail the recent mergers and acquisitions, joint ventures, collaborations, product launches and brand promotions, agreements, corporate and government deals, and partnerships, among others. The report also sheds light on the recent technological developments and product advancements in the Monoclonal Antibodies market.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample/2533

The leading market contenders listed in the report are: Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc.; Bayer AG; Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Viatris Inc.; Biogen Inc.; Thermo Fisher Scientific, Inc.; Novo Nordisk A/S; Sanofi S.A., and Teva Pharmaceutical Industries Ltd

The research study examines historic data from 2018 and 2020 to draw forecasts until 2030. The timeline makes the report an invaluable resource for readers, investors, and stakeholders looking for key insights in readily accessible documents with the information presented in the form of tables, charts, and graphs. To Visit Full Report & Table of Contents Monoclonal Antibodies Market: https://www.emergenresearch.com/industry-report/monoclonal-antibodies-market

Market Overview: The report bifurcates the Monoclonal Antibodies market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment. Segments Covered in this report are:

Source Outlook (Revenue, USD Billion; 2019-2032)

Humanized mAb

Human mAb

Murine mAb

Chimeric mAb

Indication Outlook (Revenue, USD Billion; 2019-2032)

Cancer

Breast cancer

Colorectal cancer

Lung cancer

Ovarian cancer

Others

Autoimmune Diseases

Inflammatory Diseases

Infectious Diseases

Others

Production Type Outlook (Revenue, USD Billion; 2019-2032)

In Vivo

In Vitro

The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market.

[omkarpatel]

Cytotoxic Drugs Contract Manufacturing is Estimated to Witness High Growth Owing to Significant Cost Savings

The cytotoxic drugs contract manufacturing market revolves around the development and manufacturing services provided by specialized contract manufacturing organizations (CMOs) to pharmaceutical companies. Cytotoxic drugs, commonly referred to as chemotherapy drugs, are widely used treatments for cancer and other chronic diseases. These drugs are extremely toxic in nature which necessitates specialized handling and manufacturing practices. The contract manufacturing model provides pharmaceutical companies access to sophisticated cytotoxic facilities and expertise without significant investments. The global cytotoxic drugs contract manufacturing market is estimated to be valued at US$ 6,285.2 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The key factor driving growth of the cytotoxic drugs contract manufacturing market is the significant cost savings provided by the contract manufacturing model. Developing in-house cytotoxic drug manufacturing facilities requires huge capital investments in highly specialized and regulated manufacturing units. It also necessitates maintaining expensive certifications and safety practices on an ongoing basis. Contract manufacturers are able to achieve economies of scale across multiple client projects allowing them to offer cytotoxic drug development and manufacturing services at substantially lower prices compared to in-house manufacturing. This cost advantage has led to rising adoption of contract cytotoxic drug manufacturing by pharmaceutical companies, especially small and mid-sized firms. The growth in immunotherapy and targeted cancer therapies is also expected to boost demand for cytotoxic contract manufacturing services over the forecast period. Porter's Analysis Threat of new entrants: The cytotoxic drugs contract manufacturing market requires high capital investment and strict regulatory compliances which acts as a entry barrier for new players. Bargaining power of buyers: The market has a considerable number of buyers in terms of biopharma companies. However, the specialized nature of services limits buyer's bargaining power. Bargaining power of suppliers: Due to limited number of capable contract manufacturing organizations (CMOs), suppliers have a relatively higher bargaining power in this market. Threat of new substitutes: There exist limited substitutes for cytotoxic drugs contract manufacturing as it requires specialized manufacturing facilities and high expertise. Competitive rivalry: The cytotoxic drugs contract manufacturing market experiences moderate to high competition due to presence of many global and regional players. SWOT Analysis Strength: Cytotoxic drugs contract manufacturing market has robust capabilities in terms of specialized manufacturing facilities, technologies, and expertise to produce complex large molecule injectable drugs. Weakness: Setting up drug manufacturing plants require huge capital expenditure. Drug production processes need continuous upgrading as per changing regulatory norms. Opportunity: Increasing R&D investments of biopharma companies and growing demand for biosimilars and generic injectable offerings present significant opportunities for CMOs. Threats: Stringent regulatory environment and risk of litigation due to manufacturing or quality issues are major threats for the players. Key Takeaways The global cytotoxic drugs contract manufacturing market is expected to witness high growth driven by expanding pharmaceutical outsourcing and growing monoclonal antibody (mAb) space. The global Cytotoxic Drugs Contract Manufacturing Market is estimated to be valued at US$ 6,285.2 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030.

Asia Pacific region is projected to be the fastest growing market for cytotoxic drugs contract manufacturing during the forecast period. This is attributed to rapidly increasing R&D investments by pharmaceutical companies, favorable government policies, and emerging biosimilar opportunities in countries like China, India, and South Korea. Key players operating in the cytotoxic drugs contract manufacturing are Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma Internatisonal, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group.